Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480059 | 0.83 | SMN1; SMN2 (0.39) | GNAI3GNAO1GNAI1ALDH1A1THRB | |
| SCHEMBL1307437 | 0.73 | SMN1; SMN2 (0.37) | THRBADH1BADH1AADH7 | |
| SCHEMBL12534280 | 0.71 | — | — | |
| SCHEMBL13478087 | 0.70 | HSD17B10 (0.38) | KMT2AGNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL2182415 | 0.69 | HSD17B10 (0.48) | KMT2AGNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL14431493 | 0.69 | — | — | |
| SCHEMBL791167 | 0.68 | KMT2A (0.37) | KMT2AALDH1A1 | |
| SCHEMBL13522685 | 0.68 | KMT2A (0.35) | KMT2AALDH1A1THRB | |
| SCHEMBL27755179 | 0.67 | SORT1 (0.41) | KMT2AALDH1A1THRB | |
| SCHEMBL8029443 | 0.67 | ALOX5 (0.41) | GNAI3GNAO1GNAI1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166844-A1 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20090202465-A1 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method | L'OREAL S.A. (FR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202465-A1 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method | KRT18, EYA3, PHOSPHO1 | KMT2A 935/4885GNAI3 3901/4885GNAO1 4311/4885 |
| US-20100166844-A1 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | KRT18, KRTCAP2, DSG1 | KMT2A 1629/4885GNAI3 4653/4885GNAO1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.